Weight Reduction Medicine Market Growth Boosters, Technological Advancements And New Products 2021-2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (AmericaNewsHour) —
Covering the growth of the Weight Reduction Medicine Market in regions- North America, Latin America, Europe, Asia Pacific and Middle East & Africa region, the research analysts at Kenneth Research have compiled a study in order to understand the latest industry trends and opportunities that are expected to influence the expansion of the market over the next ten years. The detailed report encloses the information on production, demand and consumer analysis related to overall consumption of the product.

The report covers the forecast and analysis of the Weight Reduction Medicine Market on a global and regional level. The study provides historical data from 2013 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the Weight Reduction Medicine Market along with the impact they have on the demand over the forecast period.

Click Here to Download Sample Report >>  https://www.kennethresearch.com/sample-request-10244417

Market Overview

The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Weight Reduction Medicine by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
        Liauid
        Tablets
Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):
        Roche
        GSK group
        Teva
        Sandoz(Novartis)
        STADA-VN J.V.Co., Ltd
        Hexal AG
        National Company For Pharmaceutical Industry
        Lunan Pharmaceutical Group Corporation
        Zein Pharmaceutical
        Hisun
        Taj Pharmaceuticals Ltd
        Kabir Life Sciences & Research
        Dm Pharma
        China Zhongshan Pharm
Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):
        Weight-reducing Aid
        Others
Region Coverage (Regional Production, Demand & Forecast by Countries etc.):
        North America (U.S., Canada, Mexico)
        Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
        Asia-Pacific (China, India, Japan, Southeast Asia etc.)
        South America (Brazil, Argentina etc.)
        Middle East & Africa (Saudi Arabia, South Africa etc.)

Request For Full Report >>https://www.kennethresearch.com/sample-request-10244417

Competitive Analysis:
The Weight Reduction Medicine Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included in this report with Porter’s five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.

Key points covered in this report:
? The historical and current data is provided in the report based on which the future projections are made and the industry analysis is performed.
? The import and export details along with consumption value and production capability of every region is mentioned in the report.
? Porter’s five forces analysis, value chain analysis,

Read more

Vaccine Trials ‘Can’t Detect’ Virus Risk Reduction: Expert

None of the trials of Covid-19 candidate vaccines can detect a reduction in serious outcomes such as hospitalisation or death, a leading public health expert said Thursday.

Writing in the BMJ medical journal, associate editor Peter Doshi warned that not even phase 3 trials under way in the race for a vaccine can prove their product will prevent people contracting Covid-19.

In a sobering essay, Doshi said those hoping for a breakthrough to end the pandemic would be disappointed, with some vaccines likely to reduce the risk of Covid-19 infection by only 30 percent.

“None of the trials currently under way are designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths,” he wrote.

“Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus.”

The World Health Organization (WHO) has identified 42 candidate vaccines in clinical trials, ten of which are in the most advanced “phase 3” stage.

This is where a vaccine’s effectiveness is tested on a large scale, generally tens of thousands of people across several continents.

But Doshi, assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, said that even the most advanced trials are evaluating mild rather than severe disease.

The World Health Organization (WHO) has identified 42 candidate vaccines in clinical trials, ten of which are in the most advanced "phase 3" stage The World Health Organization (WHO) has identified 42 candidate vaccines in clinical trials, ten of which are in the most advanced “phase 3” stage Photo: AFP / Ludovic MARIN

This may be down to the numbers of people involved in trials, he said, pointing out that the majority of confirmed Covid-19 infections involve mild or no symptoms.

And few if any current trials are designed to find out whether there is a benefit among the elderly, a key at-risk constituency.

Without enrolling frail and elderly volunteers in trials in sufficient numbers, Doshi said “there can be little basis for assuming any benefit against hospitalisation or mortality.

He added that children, immunocompromised people and pregnant women had largely been excluded from trials, making it unlikely that the experiments will address key gaps in our understanding of how Covid-19 develops differently among individuals.

Several trials have already been halted after participants became ill.

Many countries plan to prioritise vulnerable people once a vaccine is available, but Doshi said that those hoping for a miracle end to the pandemic would have to wait.

He said that several pharmaceutical firms had designed their studies “to detect a relative risk reduction of at least 30 percent in participants developing laboratory confirmed Covid-19”.

Recent studies have also confirmed that it is possible for someone to be reinfected with Covid-19, a development that may impact how governments’ form their vaccination plans.

Source Article

Read more